• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    1/10/23 2:11:52 PM ET
    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Business Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACCD alert in real time by email

    Gainers

    • Sotera Health Company (NASDAQ:SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached agreements to settle the Ethylene Oxide cases pending against Sterigenics. Sterigenics will pay the company $408 million to settle the claims.
    • Party City Holdco Inc. (NYSE:PRTY) gained 54% to $0.3193 following an Axios report suggesting The Franchise Group could be looking at acquiring the company.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares rose 51.1% to $0.1224 after gaining 4% on Monday.
    • VYNE Therapeutics Inc. (NASDAQ:VYNE) climbed 50.5% to $0.2892 after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201.
    • Elys Game Technology, Corp. (NASDAQ:ELYS) jumped 49.5% to $0.6276.
    • Boxed, Inc. (NYSE:BOXD) gained 36.6% to $0.5191 after the company announced its Spresso Saas modular solution platform is now available on Google Cloud.
    • Biora Therapeutics, Inc. (NASDAQ:BIOR) rose 35% to $2.85. HC Wainwright & Co. maintained Biora Therapeutics with a Buy.
    • DermTech, Inc. (NASDAQ:DMTK) shares climbed 32.6% to $2.88 after DermTech announced the foundational assay of its DermTech Melanoma Test (DMT) is recommended for coverage by TRICARE.
    • DatChat, Inc. (NASDAQ:DATS) gained 31.7% to $0.48 after the company announced a $2 million stock repurchase plan.
    • POET Technologies Inc. (NASDAQ:POET) gained 31.3% to $4.2750.
    • Jianzhi Education Technology Group Company Limited (NASDAQ:JZ) gained 30% to $1.5657.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) jumped 29.4% to $0.2349.
    • Oak Street Health, Inc. (NYSE:OSH) gained 28.4% to $28.99 as CVS Health is reportedly exploring an acquisition of primary care center operator.
    • BTCS Inc. (NASDAQ:BTCS) jumped 28.2% to $1.3199 after the company launched a private beta of its digital asset analytic and staking-as-a-service platform StakeSeeker.
    • Frontline plc (NYSE:FRO) rose 27.1% to $14.40. Frontline announced termination of combination agreement with Euronav.
    • Schmitt Industries, Inc. (NASDAQ:SMIT) gained 27.1% to $0.3879.
    • Prenetics Global Limited (NASDAQ:PRE) gained 25.6% to $2.3880 after the company announced its ACT Genomics received clearance from the FDA for ACTOnco.
    • NeuroPace, Inc. (NASDAQ:NPCE) jumped 25.2% to $2.04. NeuroPace announced preliminary unaudited Q4 revenue of $12.8 million and FY22 revenue of $45.5 million.
    • Bright Health Group, Inc. (NYSE:BHG) gained 24% to $0.8050 after the company announced it increased 2023 Enterprise Revenue guidance to $3.4 - $3.6 billion.
    • Frequency Therapeutics, Inc. (NASDAQ:FREQ) rose 24% to $4.13.
    • Ambrx Biopharma Inc. (NASDAQ:AMAM) jumped 23.5% to $2.62.
    • Accolade, Inc. (NASDAQ:ACCD) rose 23.5% to $9.58 after the company reported better-than-expected Q3 EPS and sales results and issued FY23 revenue guidance above estimates.
    • Kura Sushi USA, Inc. (NASDAQ:KRUS) gained 21.4% to $52.24. Kura Sushi recently reported worse-than-expected Q1 EPS and sales results.
    • Titan Medical Inc. (NASDAQ:TMDI) rose 20.4% to $1.1195.
    • Tuesday Morning Corporation (NASDAQ:TUEM) gained 19.4% to $0.74.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) climbed 17.8% to $4.4438. Summit Therapeutics said on January 6, 2023, the company held meeting to vote on increase number of authorized shares of common stock by 650 million shares.
    • Amarin Corporation plc (NASDAQ:AMRN) gained 17.2% to $1.7350 after the company reported preliminary Q4 and FY22 revenue results above estimates.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) rose 17.1% to $1.8975 despite the company turning in worse-than-expected financial results.
    • Satixfy Communications Ltd. (NYSE:SATX) gained 16.3% to $7.49.
    • Versus Systems Inc. (NASDAQ:VS) rose 15.3% to $0.6990 after jumping over 16% on Monday.
    • CureVac N.V. (NASDAQ:CVAC) gained 14.8% to $11.90.
    • Vericel Corporation (NASDAQ:VCEL) rose 14% to $27.25 after the company reported preliminary FY22 revenue results.
    • Rain Oncology Inc. (NASDAQ:RAIN) gained 13.9% to $13.23.
    • Oatly Group AB (NASDAQ:OTLY) jumped 12.3% to $2.6750 after the company announced an expansion of its partnership with Reitan to feature oat drink in coffee machines in its 7-Eleven and Pressbyrån convenience stores across Sweden.
    • Comstock Inc. (NYSE:LODE) shares rose 11.9% to $0.4498.
    • Heska Corporation (NASDAQ:HSKA) gained 10.3% to $74.34. Heska CEO and President Kevin S Wilson bought a total of 11,018 shares at an average price of $58.62.


    Losers

    • Peak Bio, Inc. (NASDAQ:PKBO) dropped 58.2% to $2.09.
    • BioAtla, Inc. (NASDAQ:BCAB) shares fell 46.2% to $4.1550 after the company provided clinical program updates and upcoming 2023 milestones.
    • BIOLASE, Inc. (NASDAQ:BIOL) fell 46.5% to $0.3705 after the company announced pricing of $9.75 million offering.
    • Rayonier Advanced Materials Inc. (NYSE:RYAM) fell 30.6% to $6.35. RBC Capital downgraded Rayonier Adv
    • Materials from Outperform to Sector Perform and lowered the price target from $9 to $8.
    • Calithera Biosciences, Inc. (NASDAQ:CALA) dipped 25.3% to $0.4931. Calithera Biosciences shares dipped around 82% on Monday after its board of directors determined to dissolve the company and liquidate its assets. Also, the company will discontinue all clinical development programs and reduce its workforce.
    • Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) fell 17.6% to $0.5510.
    • Euronav NV (NYSE:EURN) shares fell 16.9% to $13.24.
    • IsoPlexis Corporation (NASDAQ:ISO) dipped 15.3% to $1.33.
    • Lucira Health, Inc. (NASDAQ:LHDX) dropped 14.8% to $0.3438.
    • Midatech Pharma plc (NASDAQ:MTP) fell 14.7% to $0.81.
    • Berkeley Lights, Inc. (NASDAQ:BLI) dropped 13.7% to $2.2850 after the company issued FY22 revenue guidance below analyst estimates.
    • ALX Oncology Holdings Inc. (NASDAQ:ALXO) fell 12% to $9.22.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) fell 11.7% to $1.70. Virgin Orbit shared its readiness for the Start Me Up mission for a historic U.K. launch on January 9.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) fell 10.9% to $3.9812 after jumping 42% on Monday.
    • Argo Blockchain plc (NASDAQ:ARBK) fell 9.5% to $1.2850.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) fell 8.4% to $77.67 after Spruce Point Management issued a bearish report on the stock.
    • Apexigen, Inc. (NASDAQ:APGN) fell 7.2% to $1.67 after gaining around 91% on Monday.
    • Box, Inc. (NYSE:BOX) fell 6.3% to $27.96. RBC Capital downgraded Box from Sector Perform to Underperform and lowered the price target from $28 to $24.

    Also Check This Out Ethereum Remains Above This Key Level; Aptos Emerges As Top Gainer

    Get the next $ACCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD
    $ALXO
    $AMAM
    $AMRN

    CompanyDatePrice TargetRatingAnalyst
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    BioAtla Inc.
    $BCAB
    1/13/2026$4.00Buy
    Rodman & Renshaw
    Super Micro Computer Inc.
    $SMCI
    1/13/2026$26.00Sell
    Goldman
    Frontline Plc
    $FRO
    1/12/2026Neutral → Buy
    Clarksons Platou
    Sotera Health Company
    $SHC
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    Sotera Health Company
    $SHC
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    Sotera Health Company
    $SHC
    12/18/2025Outperform
    William Blair
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    SEC Filings

    View All

    SEC Form 425 filed by Bed Bath & Beyond Inc.

    425 - BED BATH & BEYOND, INC. (0001130713) (Filed by)

    2/23/26 5:11:53 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form S-8 filed by Summit Therapeutics Inc.

    S-8 - Summit Therapeutics Inc. (0001599298) (Filer)

    2/23/26 4:58:58 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Summit Therapeutics Inc.

    10-K - Summit Therapeutics Inc. (0001599298) (Filer)

    2/23/26 4:10:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Box to Host Financial Analyst Day

    Box, Inc. (NYSE:BOX), the leading Intelligent Content Management (ICM) platform, today announced that it will host its FY27 Financial Analyst Day on Thursday, March 19, 2026. Members of Box's executive management team will host a presentation followed by Q&A beginning at 2:00 p.m. ET. The in-person event will be held in Midtown Manhattan. Institutional Investors and Financial Analysts may attend in-person or virtually by pre-registering here. A live video webcast of the event will be accessible at www.boxinvestorrelations.com. An archive of the webcast will be available for replay beginning approximately one hour after the live event for a period of one year. About Box Box (NYSE:BOX

    2/23/26 4:05:00 PM ET
    $BOX
    Computer Software: Prepackaged Software
    Technology

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Rodman & Renshaw initiated coverage on BioAtla with a new price target

    Rodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00

    1/13/26 3:22:40 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on Super Micro Computer with a new price target

    Goldman resumed coverage of Super Micro Computer with a rating of Sell and set a new price target of $26.00

    1/13/26 9:18:14 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Allen Charles W bought $261,425 worth of shares (90,500 units at $2.89), increasing direct ownership by 2% to 4,666,506 units (SEC Form 4)

    4 - BTCS Inc. (0001436229) (Issuer)

    11/19/25 5:27:18 PM ET
    $BTCS
    Finance: Consumer Services
    Finance

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 3,412 shares, decreasing direct ownership by 4% to 75,322 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    2/23/26 5:31:37 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Hopper Jonathan Mark converted options into 5,325 shares and covered exercise/tax liability with 982 shares, increasing direct ownership by 7% to 71,027 units (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    2/20/26 4:06:10 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Colangelo Dominick converted options into 29,950 shares and covered exercise/tax liability with 5,657 shares, increasing direct ownership by 9% to 284,770 units (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    2/20/26 4:06:14 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    Kura Sushi USA Announces Election of Claudia Schaefer to the Company's Board of Directors

    IRVINE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Kura Sushi USA, Inc. ("Kura Sushi" or the "Company"), (NASDAQ:KRUS), a technology-enabled Japanese restaurant concept, today announced that Claudia Schaefer has been elected to serve as an independent member of the Board of Directors effective January 21, 2026. In conjunction with Ms. Schaefer's nomination, Kim Ellis did not stand for re-election as a director, also effective January 21, 2026. Hajime Uba, President, Chief Executive Officer and Chairman of Kura Sushi, stated, "We are thrilled to announce the election of Claudia to Kura Sushi USA's Board of Directors. Claudia's deep brand and marketing background makes her an excellent addit

    1/22/26 4:05:00 PM ET
    $KRUS
    Restaurants
    Consumer Discretionary

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company's in

    2/20/26 4:30:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $ACCD
    $ALXO
    $AMAM
    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Versus Systems Inc.

    SC 13G/A - Versus Systems Inc. (0001701963) (Subject)

    11/14/24 7:30:32 PM ET
    $VS
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care